Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 18.

Journal Article

Brown, Jennifer R., Moslehi, Javid, Ewer, Michael S., O'Brien, Susan M., Ghia, Paolo ORCID: 0000-0003-3750-7342, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Coutre, Steven E., Dilhuydy, Marie-Sarah, Cramer, Paula, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Treon, Steven, Liu, Emily Y., Chang, Stephen, Bista, Amulya, Vempati, Rama, Boornazian, Lisa, Valentino, Rudolph, Reddy, Vijay, Mahler, Michelle, Yang, Huiying, Graef, Thorsten and Burger, Jan A. (2019). Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br. J. Haematol., 184 (4). S. 558 - 570. HOBOKEN: WILEY. ISSN 1365-2141

Brown, Jennifer R., Moslehi, Javid, O'Brien, Susan, Ghia, Paolo ORCID: 0000-0003-3750-7342, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Kipps, Thomas J., Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F., Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle and Burger, Jan A. (2017). Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 102 (10). S. 1796 - 1806. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian ORCID: 0000-0003-2644-1050, Pristupa, Aleksander, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L., Dilhuydy, Marie-Sarah, Pylypenko, Halyna, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Villa, Diego, Samoilova, Olga, Panagiotidis, Panagiots, Goy, Andre ORCID: 0000-0001-5125-6522, Mato, Anthony, Pavlovsky, Miguel A., Karlsson, Claes, Mahler, Michelle, Salman, Mariya, Sun, Steven, Phelps, Charles, Balasubramanian, Sriram, Howes, Angela, Hallek, Michael, Assouline, S., Bence-Bruckler, I., Buckstein, R., Fraser, G., Larratt, L., Minuk, L., Villa, D., Angevine, A., Bartlett, N., Bixby, D., Caimi, P., Chanan-Khan, A., Craig, M., Forero-Torres, A., Ganguly, S., Goy, A., Heffner, L., Hermann, R., Lansigan, F., Leis, J., Letzer, J., Link, B., Liu, D., McCaul, K., McGuire, E., Skinner, W., Starodub, A., Stuart, R., Thirman, M., Tirumali, N., Yang, J., Janssens, A., Offner, F., Van den Neste, E., Van Hoof, A., Mayer, J., Novak, J., Trneny, M., Cartron, G., Dartigeas, C., Dilhuydy, M., Ghez, D., Haioun, C., Leblond, V., Salles, G., Balser, C., Cramer, P., Dreger, P., Durig, J., Eckart, M., Heinrich, B., Illmer, T., Jentsch-Ullrich, K., Pfreundschuh, M., Schetelig, J., Schlag, R., Soling, U., Stilgenbaue, S., Anagnostopoulos, A., Dimopoulos, A., Panagiotidis, P., Vrakidou, E., Bairey, O., Ben Yehuda, D., Braester, A., Fineman, R., Herishanu, Y., Nagler, A., Ruchlemer, R., Tadmor, T., Grosicki, S., Homenda, W., Jurczak, W., Pluta, A., Woszczyk, D., Espirito Santo, A., Luis, R., Raposo, J., Viveiros, C., Alexeeva, J., Dunaev, Y., Golubeva, M., Khuageva, N., Loginov, A., Lysenko, I., Osmanov, E., Pavlov, V., Pristupa, A., Proydakov, A., Rossiev, V., Samarina, I., Samoilova, O., Serduk, O., Shneider, T., Udovitsa, D., Voloshin, S., Gayoso, J., Gonzalez, M., Gonzalez Barca, E., Hernandez Rivas, J., Jargue, I., Loscertales, J., Karlsson, C., Sender, M., Aktan, M., Arslan, O., Demirkan, F., Ferhanoglu, B., Kaynar, L., Sayinalp, N., Vaural, F., Yagci, M., Dyagil, I., Kaplan, P., Masliak, Z., Oliynyk, H., Popovska, T., Pylypenko, H., Rekhtman, G., Dearden, C., Morley, N., Moss, P., Rule, S., Pavlovsky, M., Riveros, D., Santucci-Silva, R., Romeo, M., Scheliga, A., Salazar, L., Gomez, D., Ramirez, E. and Jung, C. (2016). Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol., 17 (2). S. 200 - 212. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Howes, Angela and Hallek, Michael (2015). Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Chanan-Khan, Asher, Cramer, Paula, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian, Pristupa, Aleksander, Dilhuydy, Marie Sarah, Goy, Andre ORCID: 0000-0001-5125-6522, Mato, Anthony R., Damle, Rajendra, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Schaffer, Michael, Howes, Angela and Balasubramanian, Sriram (2015). Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Chanan-Khan, Asher, Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Masha, Howes, Angela and Hallek, Michael (2015). Ibrutinib combined with bendamustine/rituximab (BR) in previously treated small lymphocytic lymphoma (SLL): analysis of patients in the HELIOS trial. Leuk. Lymphoma, 56. S. 92 - 94. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Chanan-Khan, Asher Alban Akmal, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Alexander, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Mahler, Michelle, Salman, Mariya, Howes, Angela J. and Hallek, Michael J. (2015). Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. J. Clin. Oncol., 33 (18). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Cramer, Paula, Chanan-Khan, Asher, Fraser, Graeme, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Schaffer, Michael, Balasubramanian, Sriram, Howes, Angela and Hallek, Michael (2015). Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, Chanan-Khan, Asher, Fraser, Graeme, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Barlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Masha, Howes, Angela and Hallek, Michael (2015). Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial. Leuk. Lymphoma, 56. S. 93 - 95. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, Fraser, Graeme, Santucci-Silva, Rodrigo, Grosicki, Sebastian ORCID: 0000-0003-2644-1050, Dilhuydy, Marie-Sarah, Janssens, Ann, Loscertales, Javier, Rule, Simon, Goy, Andre ORCID: 0000-0001-5125-6522, Traina, Shana, Chan, Eric K. H., Diels, Joris, Sengupta, Nishan, Mahler, Michelle, Salman, Mariya, Howes, Angela and Chanan-Khan, Asher (2018). Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. Leuk. Lymphoma, 59 (9). S. 2075 - 2085. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Fraser, Graeme, Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Masha, Howes, Angela and Hallek, Michael (2015). Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial. Leuk. Lymphoma, 56. S. 98 - 101. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Goy, Andre ORCID: 0000-0001-5125-6522, Avigdor, Abraham, Rule, Simon, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Howes, Angela J., Balasubramanian, Sriram and Chanan-Khan, Asher Alban Akmal (2016). Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Hallek, Michael, Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Mahler, Michelle, Phelps, Charles, Salman, Mariya, Howes, Angela and Chanan-Khan, Asher (2017). Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. Leuk. Lymphoma, 58. S. 192 - 195. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Hallek, Michael, Kay, Neil E., Osterborg, Anders, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Wan, Ying, Sun, Steven, Zhuang, Sen Hong and Howes, Angela (2015). The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol., 11 (1). S. 51 - 60. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Kipps, Thomas J., Fraser, Graeme, Coutre, Steven E., Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Byrd, John C., O'Brien, Susan M., Dilhuydy, Marie-Sarah, Hillmen, Peter, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Eckert, Karl, Solman, Isabelle G., Balasubramanian, Sriram, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle F. and Hallek, Michael (2019). Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin. Lymphoma Myeloma Leuk., 19 (11). S. 715 - 729. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Kipps, Thomas J., Mahler, Michelle, Fraser, Graeme, Coutre, Steven, Brown, Jennifer, Barrientos, Jacqueline, Barr, Paul ORCID: 0000-0002-9733-401X, Byrd, John C., O'Brien, Susan, Dilhuydy, Marie Sarah, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher, Salman, Mariya, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle, Hallek, Michael and Hillmen, Peter (2017). Outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) with high-risk prognostic factors in an integrated analysis of 3 randomized phase 3 studies. Leuk. Lymphoma, 58. S. 10 - 13. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Lavezzi, Silvia Maria, de Jong, Jan, Neyens, Martine, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Bartlett, Nancy ORCID: 0000-0001-8470-394X, Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Goy, Andre ORCID: 0000-0001-5125-6522, Ganguly, Siddhartha, Salman, Mariya, Howes, Angela, Mahler, Michelle, De Nicolao, Giuseppe and Poggesi, Italo (2019). Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Pharm. Res., 36 (7). NEW YORK: SPRINGER/PLENUM PUBLISHERS. ISSN 1573-904X

Traina, Shana, Fraser, Graeme, Cramer, Paula, Silva, Rodrigo Santucci, Grosicki, Sebastian, Dilhuydy, Marie Sarah, Mahler, Michelle, Salman, Mariya and Howes, Angela (2015). Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Sat Oct 23 04:04:04 2021 CEST.